Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors.

Moding EJ, Liang R, Lartey FM, Maxim PG, Sung A, Diehn M, Loo BW Jr, Gensheimer MF.

Clin Lung Cancer. 2019 Jul 4. pii: S1525-7304(19)30142-1. doi: 10.1016/j.cllc.2019.05.015. [Epub ahead of print]

PMID:
31377143
2.

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.

Hellyer JA, Stehr H, Das M, Padda SK, Ramchandran K, Neal JW, Diehn M, Wakelee HA.

Lung Cancer. 2019 Aug;134:42-45. doi: 10.1016/j.lungcan.2019.05.002. Epub 2019 May 3.

PMID:
31319993
3.

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.

Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA.

Cell. 2019 Jul 25;178(3):699-713.e19. doi: 10.1016/j.cell.2019.06.011. Epub 2019 Jul 4.

PMID:
31280963
4.

FLT-PET-CT for the Detection of Disease Recurrence After Stereotactic Ablative Radiotherapy or Hyperfractionation for Thoracic Malignancy: A Prospective Pilot Study.

Hiniker SM, Sodji Q, Quon A, Gutkin PM, Arksey N, Graves EE, Chin FT, Maxim PG, Diehn M, Loo BW Jr.

Front Oncol. 2019 May 31;9:467. doi: 10.3389/fonc.2019.00467. eCollection 2019.

5.

Determining cell type abundance and expression from bulk tissues with digital cytometry.

Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, Diehn M, Alizadeh AA.

Nat Biotechnol. 2019 Jul;37(7):773-782. doi: 10.1038/s41587-019-0114-2. Epub 2019 May 6.

PMID:
31061481
6.

Increases in Serial Pretreatment 18F-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy.

Prionas ND, von Eyben R, Yi E, Aggarwal S, Shaffer J, Bazan J, Eastham D, Maxim PG, Graves EE, Diehn M, Gensheimer MF, Loo BW Jr.

Adv Radiat Oncol. 2018 Nov 26;4(2):429-437. doi: 10.1016/j.adro.2018.11.006. eCollection 2019 Apr-Jun.

7.

SABR-COMET: harbinger of a new cancer treatment paradigm.

Loo BW Jr, Diehn M.

Lancet. 2019 May 18;393(10185):2013-2014. doi: 10.1016/S0140-6736(19)30278-8. Epub 2019 Apr 11. No abstract available.

PMID:
30982688
8.

Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.

Wang SXY, Zhang BM, Wakelee HA, Koontz MZ, Pan M, Diehn M, Kunder CA, Neal JW.

Anticancer Drugs. 2019 Jun;30(5):537-541. doi: 10.1097/CAD.0000000000000765.

PMID:
30762593
9.

Reply to J. Wang et al.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas O, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA.

J Clin Oncol. 2019 Mar 20;37(9):755-757. doi: 10.1200/JCO.18.01907. Epub 2019 Feb 12. No abstract available.

PMID:
30753108
10.

High-resolution experimental and computational electrophysiology reveals weak β-lactam binding events in the porin PorB.

Bartsch A, Llabrés S, Pein F, Kattner C, Schön M, Diehn M, Tanabe M, Munk A, Zachariae U, Steinem C.

Sci Rep. 2019 Feb 4;9(1):1264. doi: 10.1038/s41598-018-37066-9.

11.

Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA.

Dudley JC, Schroers-Martin J, Lazzareschi DV, Shi WY, Chen SB, Esfahani MS, Trivedi D, Chabon JJ, Chaudhuri AA, Stehr H, Liu CL, Lim H, Costa HA, Nabet BY, Sin MLY, Liao JC, Alizadeh AA, Diehn M.

Cancer Discov. 2019 Apr;9(4):500-509. doi: 10.1158/2159-8290.CD-18-0825. Epub 2018 Dec 21.

PMID:
30578357
12.

The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.

Starkov P, Aguilera TA, Golden DI, Shultz DB, Trakul N, Maxim PG, Le QT, Loo BW, Diehn M, Depeursinge A, Rubin DL.

Br J Radiol. 2019 Feb;92(1094):20180228. doi: 10.1259/bjr.20180228. Epub 2018 Nov 20.

PMID:
30457885
13.

Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.

Nguyen KH, Stehr H, Zhou L, Nguyen AH, Hiep PN, Van Cau N, Duy PC, Thorp R, Wakelee HA, Diehn M, Neal JW.

J Glob Oncol. 2018 Nov;4:1-9. doi: 10.1200/JGO.18.00086.

PMID:
30422746
14.

Genomic Feature Selection by Coverage Design Optimization.

Reid S, Newman AM, Diehn M, Alizadeh AA, Tibshirani R.

J Appl Stat. 2018;45(14):2658-2676. doi: 10.1080/02664763.2018.1432577. Epub 2018 Feb 7.

15.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
16.

Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer.

Harris JP, Nwachukwu C, Qian Y, Pollom E, Loo BW, Das M, Diehn M.

Lung Cancer. 2018 Oct;124:76-85. doi: 10.1016/j.lungcan.2018.07.033. Epub 2018 Jul 23.

PMID:
30268484
17.

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA.

J Clin Oncol. 2018 Oct 1;36(28):2845-2853. doi: 10.1200/JCO.2018.78.5246. Epub 2018 Aug 20.

PMID:
30125215
18.

18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy.

Qian Y, Von Eyben R, Liu Y, Chin FT, Miao Z, Apte S, Carter JN, Binkley MS, Pollom EL, Harris JP, Prionas ND, Kissel M, Simmons A, Diehn M, Shultz DB, Brown JM, Maxim PG, Koong AC, Graves EE, Loo BW Jr.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1183-1192. doi: 10.1016/j.ijrobp.2018.03.045. Epub 2018 Apr 18.

PMID:
29859786
19.

GFPT2-Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma.

Zhang W, Bouchard G, Yu A, Shafiq M, Jamali M, Shrager JB, Ayers K, Bakr S, Gentles AJ, Diehn M, Quon A, West RB, Nair V, van de Rijn M, Napel S, Plevritis SK.

Cancer Res. 2018 Jul 1;78(13):3445-3457. doi: 10.1158/0008-5472.CAN-17-2928. Epub 2018 May 14.

20.

Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.

Chin AL, Kumar KA, Guo HH, Maxim PG, Wakelee H, Neal JW, Diehn M, Loo BW Jr, Gensheimer MF.

Clin Lung Cancer. 2018 Sep;19(5):e581-e588. doi: 10.1016/j.cllc.2018.04.003. Epub 2018 Apr 19.

PMID:
29759331
21.

Circulating tumor DNA testing in advanced non-small cell lung cancer.

Moding EJ, Diehn M, Wakelee HA.

Lung Cancer. 2018 May;119:42-47. doi: 10.1016/j.lungcan.2018.02.019. Epub 2018 Mar 2. Review.

PMID:
29656751
22.

A Feasibility Study of Single-inhalation, Single-energy Xenon-enhanced CT for High-resolution Imaging of Regional Lung Ventilation in Humans.

Pinkham DW, Negahdar M, Yamamoto T, Mittra E, Diehn M, Nair VS, Keall PJ, Maxim PG, Loo BW Jr.

Acad Radiol. 2019 Jan;26(1):38-49. doi: 10.1016/j.acra.2018.03.006. Epub 2018 Mar 29.

PMID:
29606339
23.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5. Review.

PMID:
29504847
24.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

Arch Pathol Lab Med. 2018 Oct;142(10):1242-1253. doi: 10.5858/arpa.2018-0901-SA. Epub 2018 Mar 5. Review.

PMID:
29504834
25.

Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma.

Przybyl J, Chabon JJ, Spans L, Ganjoo KN, Vennam S, Newman AM, Forgó E, Varma S, Zhu S, Debiec-Rychter M, Alizadeh AA, Diehn M, van de Rijn M.

Clin Cancer Res. 2018 Jun 1;24(11):2688-2699. doi: 10.1158/1078-0432.CCR-17-3704. Epub 2018 Feb 20.

26.

A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer.

Lee J, Li B, Cui Y, Sun X, Wu J, Zhu H, Yu J, Gensheimer MF, Loo BW Jr, Diehn M, Li R.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1098-1106. doi: 10.1016/j.ijrobp.2018.01.006. Epub 2018 Jan 10.

PMID:
29439884
27.

Endothelial deletion of Ino80 disrupts coronary angiogenesis and causes congenital heart disease.

Rhee S, Chung JI, King DA, D'amato G, Paik DT, Duan A, Chang A, Nagelberg D, Sharma B, Jeong Y, Diehn M, Wu JC, Morrison AJ, Red-Horse K.

Nat Commun. 2018 Jan 25;9(1):368. doi: 10.1038/s41467-017-02796-3.

28.

Line-Enhanced Deformable Registration of Pulmonary Computed Tomography Images Before and After Radiation Therapy With Radiation-Induced Fibrosis.

King M, Sensakovic WF, Maxim P, Diehn M, Loo BW, Xing L.

Technol Cancer Res Treat. 2018 Jan 1;17:1533034617749419. doi: 10.1177/1533034617749419.

29.

The Future of Radiobiology.

Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT, Willers H, Wouters BG, Bernhard EJ.

J Natl Cancer Inst. 2018 Apr 1;110(4):329-340. doi: 10.1093/jnci/djx231.

30.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG.

Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.

31.

Deactivated CRISPR Associated Protein 9 for Minor-Allele Enrichment in Cell-Free DNA.

Aalipour A, Dudley JC, Park SM, Murty S, Chabon JJ, Boyle EA, Diehn M, Gambhir SS.

Clin Chem. 2018 Feb;64(2):307-316. doi: 10.1373/clinchem.2017.278911. Epub 2017 Oct 16.

32.

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gensheimer MF, West RB, Shrager JB, Neal JW, Wakelee HA, Loo BW Jr, Alizadeh AA, Diehn M.

Cancer Discov. 2017 Dec;7(12):1394-1403. doi: 10.1158/2159-8290.CD-17-0716. Epub 2017 Sep 24.

33.

Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer.

Gensheimer MF, Hong JC, Chang-Halpenny C, Zhu H, Eclov NCW, To J, Murphy JD, Wakelee HA, Neal JW, Le QT, Hara WY, Quon A, Maxim PG, Graves EE, Olson MR, Diehn M, Loo BW Jr.

Radiother Oncol. 2017 Nov;125(2):338-343. doi: 10.1016/j.radonc.2017.08.007. Epub 2017 Aug 19.

PMID:
28830717
34.

Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC.

Lee J, Cui Y, Sun X, Li B, Wu J, Li D, Gensheimer MF, Loo BW Jr, Diehn M, Li R.

Eur Radiol. 2018 Feb;28(2):736-746. doi: 10.1007/s00330-017-4996-4. Epub 2017 Aug 7.

35.

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.

Li B, Cui Y, Diehn M, Li R.

JAMA Oncol. 2017 Nov 1;3(11):1529-1537. doi: 10.1001/jamaoncol.2017.1609.

36.

Data normalization considerations for digital tumor dissection.

Newman AM, Gentles AJ, Liu CL, Diehn M, Alizadeh AA.

Genome Biol. 2017 Jul 5;18(1):128. doi: 10.1186/s13059-017-1257-4.

37.

Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors.

Qian Y, Zhu H, Pollom EL, Durkee BY, Chaudhuri AA, Gensheimer MF, Diehn M, Shultz DB, Loo BW Jr.

Pract Radiat Oncol. 2017 Nov - Dec;7(6):e525-e529. doi: 10.1016/j.prro.2017.04.005. Epub 2017 Apr 13.

PMID:
28669706
38.

Practical workflow for rapid prototyping of radiation therapy positioning devices.

Gensheimer MF, Bush K, Juang T, Herzberg B, Villegas M, Maxim PG, Diehn M, Loo BW Jr.

Pract Radiat Oncol. 2017 Nov - Dec;7(6):442-445. doi: 10.1016/j.prro.2017.05.004. Epub 2017 May 13. No abstract available.

PMID:
28668669
39.

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT.

BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.

40.

Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839.

Edelman MJ, Hu C, Le QT, Donington JS, D'Souza WD, Dicker AP, Loo BW, Gore EM, Videtic GMM, Evans NR, Leach JW, Diehn M, Feigenberg SJ, Chen Y, Paulus R, Bradley JD.

J Thorac Oncol. 2017 Sep;12(9):1413-1420. doi: 10.1016/j.jtho.2017.06.007. Epub 2017 Jun 16.

41.

A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.

Harris JP, Patel MI, Loo BW, Wakelee HA, Diehn M.

Lung Cancer. 2017 Jun;108:173-182. doi: 10.1016/j.lungcan.2017.03.017. Epub 2017 Mar 29.

42.

High-throughput sequencing for noninvasive disease detection in hematologic malignancies.

Scherer F, Kurtz DM, Diehn M, Alizadeh AA.

Blood. 2017 Jul 27;130(4):440-452. doi: 10.1182/blood-2017-03-735639. Epub 2017 Jun 9. Review.

43.

Normal Tissue Constraints for Abdominal and Thoracic Stereotactic Body Radiotherapy.

Pollom EL, Chin AL, Diehn M, Loo BW, Chang DT.

Semin Radiat Oncol. 2017 Jul;27(3):197-208. doi: 10.1016/j.semradonc.2017.02.001. Epub 2017 Feb 20. Review.

PMID:
28577827
44.

Pulmonary function after lung tumor stereotactic ablative radiotherapy depends on regional ventilation within irradiated lung.

Binkley MS, King MT, Shrager JB, Bush K, Chaudhuri AA, Popat R, Gensheimer MF, Maxim PG, Henry Guo H, Diehn M, Nair VS, Loo BW Jr.

Radiother Oncol. 2017 May;123(2):270-275. doi: 10.1016/j.radonc.2017.03.021. Epub 2017 Apr 28.

PMID:
28460826
45.

Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.

Offin M, Chabon JJ, Razavi P, Isbell JM, Rudin CM, Diehn M, Li BT.

J Oncol. 2017;2017:4517834. doi: 10.1155/2017/4517834. Epub 2017 Mar 14. Review.

46.

ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.

Chuang JC, Stehr H, Liang Y, Das M, Huang J, Diehn M, Wakelee HA, Neal JW.

J Thorac Oncol. 2017 May;12(5):833-842. doi: 10.1016/j.jtho.2017.01.023. Epub 2017 Feb 4.

47.

Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes.

Jiang D, Turner B, Song J, Li R, Diehn M, Le QT, Khatri P, Koong AC.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00073. Epub 2017 Jul 26.

48.

Reprogramming the immunological microenvironment through radiation and targeting Axl.

Aguilera TA, Rafat M, Castellini L, Shehade H, Kariolis MS, Hui AB, Stehr H, von Eyben R, Jiang D, Ellies LG, Koong AC, Diehn M, Rankin EB, Graves EE, Giaccia AJ.

Nat Commun. 2016 Dec 23;7:13898. doi: 10.1038/ncomms13898.

49.

Molecular profiling of single circulating tumor cells from lung cancer patients.

Park SM, Wong DJ, Ooi CC, Kurtz DM, Vermesh O, Aalipour A, Suh S, Pian KL, Chabon JJ, Lee SH, Jamali M, Say C, Carter JN, Lee LP, Kuschner WG, Schwartz EJ, Shrager JB, Neal JW, Wakelee HA, Diehn M, Nair VS, Wang SX, Gambhir SS.

Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):E8379-E8386. doi: 10.1073/pnas.1608461113. Epub 2016 Dec 12.

50.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Nov 14;7:13513. doi: 10.1038/ncomms13513. No abstract available.

Supplemental Content

Support Center